IP Verse

Crystals - EP3275871

The patent EP3275871 was granted to Nippon Shinyaku on Jan 15, 2020. The application was originally filed on Jun 25, 2010 under application number EP17186415A. The patent is currently recorded with a legal status of "Revoked".

EP3275871

NIPPON SHINYAKU
Application Number
EP17186415A
Filing Date
Jun 25, 2010
Status
Revoked
Jun 27, 2024
Publication Date
Jan 15, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKOct 15, 2020ELKINGTON AND FIFE -

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO02088084
DESCRIPTIONWO2009107736
DESCRIPTIONWO2009154246
DESCRIPTIONWO2009157396
DESCRIPTIONWO2009157397
DESCRIPTIONWO2009157398
OPPOSITIONEP1400518
OPPOSITIONWO02088084
SEARCHEP1400518

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- AKIO NAKAMURA, "Synthesis and evaluation of Nacylsulfonamide and N- acylsuffonylurea prodrugs of a prostacyclin receptor agonist", Bioorganic & Medicinal Chemistry, vol. 15, pages 7720 - 7725
OPPOSITION- Anonymous, "Phases of clinical research, Wikipedia", (20191216), pages 1 - 8, URL: https://en.wikipedia.org/wiki/Phases_of_clinical_research, XP055745446
OPPOSITION- BAVIN M, "Polymorphism in Process Development", Chemistry & Industry, (19890821), pages 527 - 529, XP001180136
OPPOSITION- "Chapter 11 Purification", Leonard J; Lygo And G Proctor B, Advanced Practical Organic Chemistry Second Edition,, Chapman & Hall, (1998), pages 184 - 187, XP055539235
OPPOSITION- CLARE ANDERTON, "A valuable technique for polymorph screening", EUROPEAN PHARMACEUTICAL REVIEW, (2004), vol. 9, no. 2, pages 68 - 74, XP002538579
OPPOSITION- J. Keith Guillory, "Chapter 5 - Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids", J. Keith Guillory, HARRY G. BRITTAIN, Polymorphisms in Pharmaceutical Solids, 1999, Marcel Dekker, Inc. New York • Basel, pages 2pp,183 - 226, XP009519909
OPPOSITION- JOHN F. BAUER, "Polymorphism-A Critical Consideration in Pharmaceutical Development, Manufacturing, and Stability", Journal of Validation Technology,, (2008), pages 15 - 23, XP055517809
OPPOSITION- Rolf Hilfiker, POLYMORPHISM IN THE PHARMACEUTICAL INDUSTRY, Weinheim, Germany, Wiley-VCH Verlag GmbH, (2006), pages 7 - 13, 211, 212, XP055518266
OPPOSITION- TERRY THRETFALL, "Structural and Thermodynamic Explanations of Ostwald's Rule", Organic Process Res&Devel, (20030000), vol. 7, pages 1017 - 1027
OPPOSITION- The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use, "POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TOSUPPORT CLINICAL TRIALS WITH A SINGLE MICRODOSE", CPMP/SWP/2599/02, (20030123), pages 1pp, 1 - 3, XP055745444
OPPOSITION- Alfons Grunenberg, "Polymorphie und Thermische Analyse pharmazeutischer Wirkstoffe", Pharmazie in unserer Zeit, (1997), vol. 26, no. 5, pages 224 - 231, XP055745450
OPPOSITION- M.R. CAIRA, "Crystalline Polymorphisms of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, (1998), vol. 198, pages 163 - 208, XP001156954
OPPOSITION- JONATHAN M MILLER; ET AL, "Solvent Systems for Crystallization and Polymorph Selection", JONATHAN M MILLER; ET AL, Patrick Augustijns; Marcus E Brewster, Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics, Springer New York, New York, NY, USA, (20070608), pages 53 - 109, doi:10.1007/978-0-387-69154-1_3, XP009519509
OPPOSITION- Asaki; Hamamoto T; Sugiyama T; Kuwano Y; Kuwabara K; K, "Structure-activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists", Bioorganic and Medicinal Chemistry, (2007), vol. 15, doi:10.1016/j.bmc.2007.08.010, pages 6692 - 6704, XP022244799
OPPOSITION- WENDY I. CROSS, "A Whole Output Strategy for Polymorph Screening: Combining Crystal Structure Prediction, Graph Set Analysis, and Targeted Crystallization Experiments in the Case of Diflunisal", Crystal Growth & Design, vol. 3, no. 2, doi:10.1021/cg025589n, pages 151 - 158, XP055518274
OPPOSITION- NAIR RODRIGUEZ-HOMEDO et al., "Significance of Controlling Crystallization Mechanisms and Kinetics in Pharmaceutical Systems", J Pharm Sci, (19990707), vol. 88, doi:10.1021/js980490h, pages 651 - 660, XP001096590
OPPOSITION- Stephen Byrn; Pfeiffer Ralph; Ganey Michael; Hoiberg Charles; Poochikian Guirag, "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (199507), vol. 12, no. 7, pages 945 - 954, XP000996386
OPPOSITION- KUWANO KEIICHI; HASHINO ASAMI; ASAKI TETSUO; HAMAMOTO TAISUKE; YAMADA TETSUHIRO; OKUBO KAORI; KUWABARA KENJI, "2-{4-[(5,6Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)- N(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist Prodrug", The Journal of Pharmacology and Experimental Therapeutics, (200709), vol. 322, no. 3, doi:10.1124/JPET.107.124248, pages 1181 - 1188, XP002670411

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents